Document is current

Any future updates will be listed below

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Crossref DOI link: https://doi.org/10.1038/s41416-022-02043-7

Published Online: 2022-11-02

Published Print: 2022-12-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark